These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38704786)

  • 1. Prognostic value of combining clinical factors,
    Lue KH; Chen YH; Chu SC; Lin CB; Wang TF; Liu SH
    Ann Nucl Med; 2024 Aug; 38(8):647-658. PubMed ID: 38704786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
    Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
    PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Semiquantitative parameters of
    Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    Wang D; Zhang M; Gao X; Yu L
    PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of 18 F-FDG PET-based radiomics and deep learning in predicting regional lymph node metastasis in patients with resectable lung adenocarcinoma: a cross-scanner and temporal validation study.
    Lue KH; Chen YH; Chu SC; Chang BS; Lin CB; Chen YC; Lin HH; Liu SH
    Nucl Med Commun; 2023 Dec; 44(12):1094-1105. PubMed ID: 37728592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung.
    Ng KS; King Sun C; Boom Ting K; Ting Kun AY
    Eur J Radiol; 2020 Feb; 123():108780. PubMed ID: 31846863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma.
    Jiang M; Guo X; Chen P; Zhang X; Gao Q; Zhang J; Zheng J
    PeerJ; 2024; 12():e16807. PubMed ID: 38250731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of intratumor metabolic and heterogeneity parameters on [
    Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W
    Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of multi-center
    Zuo Y; Liu L; Chang C; Yan H; Wang L; Sun D; Ruan M; Lei B; Xia X; Xie W; Song S; Huang G
    Med Phys; 2024 Jul; 51(7):4872-4887. PubMed ID: 38285641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients.
    Liao X; Cui Y; Chen X; Di L; Tong Z; Liu M; Wang R
    Nucl Med Commun; 2020 Nov; 41(11):1210-1217. PubMed ID: 32815896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of interim
    Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of
    Li S; Li Y; Zhao M; Wang P; Xin J
    Korean J Radiol; 2022 Sep; 23(9):921-930. PubMed ID: 36047542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
    Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
    AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Ishimura M; Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Murota M; Kanaji N; Nishiyama Y
    Sci Rep; 2023 Apr; 13(1):6742. PubMed ID: 37185611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study.
    Wang N; Zhang Y; Wu J; Zhu Y; Wu Y; Huang B; Zhang R; Fan J; Nie X
    Clin Transl Oncol; 2024 Jul; 26(7):1696-1707. PubMed ID: 38430418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.